Earnings summaries and quarterly performance for 10x Genomics.
Executive leadership at 10x Genomics.
Board of directors at 10x Genomics.
Research analysts who have asked questions during 10x Genomics earnings calls.
KM
Kyle Mikson
Canaccord Genuity
4 questions for TXG
Also covers: AKYA, BDSX, CSTL +12 more
Michael Ryskin
Bank of America Merrill Lynch
4 questions for TXG
Also covers: A, ALGN, AVTR +28 more
Patrick Donnelly
Citi
4 questions for TXG
Also covers: A, AVTR, BIO +22 more
MC
Mason Carrico
Stephens Inc.
3 questions for TXG
Also covers: AKYA, CDNA, CSTL +13 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
3 questions for TXG
Also covers: A, ADPT, AVTR +21 more
PS
Puneet Souda
Leerink Partners
3 questions for TXG
Also covers: A, ABCL, BRKR +20 more
TS
Tejas Savant
Morgan Stanley
3 questions for TXG
Also covers: ADPT, AKYA, AVTR +19 more
Tycho Peterson
Jefferies
3 questions for TXG
Also covers: A, AVTR, BIO +22 more
Dan Arias
Stifel Financial Corp.
2 questions for TXG
Also covers: A, GH, ILMN +9 more
DA
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
2 questions for TXG
Also covers: A, AVTR, CDXS +15 more
Daniel Brennan
TD Cowen
2 questions for TXG
Also covers: A, ADPT, AVTR +24 more
Douglas Schenkel
Wolfe Research, LLC
2 questions for TXG
Also covers: A, AVTR, BRKR +21 more
Luke Sergott
Barclays
2 questions for TXG
Also covers: A, AVTR, BRKR +19 more
Madeline Mollman
Wolfe Research, LLC
2 questions for TXG
Also covers: MRVI, PACB, TWST
ML
Matthew Larew
William Blair & Company
2 questions for TXG
Also covers: AMED, ATR, DNA +10 more
Rachel Vatnsdal
JPMorgan Chase & Co.
2 questions for TXG
Also covers: A, AKYA, AVTR +11 more
SN
Subhalaxmi Nambi
Guggenheim Securities
2 questions for TXG
Also covers: AKYA, BRKR, CSTL +15 more
DB
Dan Brennan
UBS
1 question for TXG
Also covers: A, ADPT, DHR +10 more
DL
Daniel Leonard
Stifel Financial Corp.
1 question for TXG
Also covers: A, AVTR, BIO +15 more
Jacob Krahenbuhl
William Blair
1 question for TXG
Also covers: MASS
Jaden
JPMorgan Chase & Co.
1 question for TXG
KB
Kyle Boucher
TD Cowen
1 question for TXG
Also covers: LAB, MYGN, SEER +2 more
L
Lauren
Jefferies Financial Group Inc.
1 question for TXG
Also covers: NEO
LL
Lu Li
Scotiabank
1 question for TXG
Also covers: FLGT, HOLX, MYGN +2 more
MS
Matt Sykes
William Blair & Company, L.L.C.
1 question for TXG
RV
Rachel Vatnsdal Olson
JPMorgan
1 question for TXG
Also covers: A, ADPT, AKYA +14 more
Salem Salem
Barclays
1 question for TXG
Also covers: GH, IQV, PACB +3 more
Thomas VonDerVellen
Guggenheim Securities, LLC
1 question for TXG
Also covers: NEO
Recent press releases and 8-K filings for TXG.
10x Genomics Reports Preliminary 2025 Results and Strategic Growth Initiatives
TXG
Earnings
New Projects/Investments
Revenue Acceleration/Inflection
- 10x Genomics reported preliminary Full-Year 2025 Revenue of approximately $643 million, which includes $44 million from patent litigation settlements, and Q4 2025 Revenue of approximately $166 million.
- The company's cash balance exceeded $520 million at year-end 2025, representing a growth of over $100 million compared to year-end 2024.
- Growth was driven by Chromium consumables reactions increasing over 20% and Spatial Consumables revenue growing 19% in 2025.
- 10x Genomics launched multiple new products and expanded its installed base to 6,400+ cumulative Chromium instruments and 1,500+ cumulative Spatial instruments sold as of December 31, 2025.
- The company is advancing into future diagnostic applications, including developing internal CLIA lab capabilities and forming key academic collaborations for novel diagnostics development in cancer and autoimmune disease.
Jan 12, 2026, 4:15 PM
10x Genomics Reports Preliminary Q4 and Full Year 2025 Results and Outlines Strategic Initiatives
TXG
Earnings
Guidance Update
New Projects/Investments
- 10x Genomics announced preliminary Q4 2025 revenue of $166 million and full year 2025 revenue of $599 million, exceeding its Q4 guide, and reported a balance sheet with over $500 million in cash after generating $40 million in Q4.
- The company highlighted strong product momentum, with the Flex assay becoming its most popular single cell assay by volume and Xenium driving spatial growth due to customer preference for its direct imaging approach.
- Strategic initiatives include a partnership with the Cancer Research Institute to build a data set for immunotherapy, collaborations with Dana-Farber Cancer Institute and Brigham and Women's Hospital for oncology and autoimmunity applications, and plans to establish a CLIA lab for diagnostics.
- Management anticipates macro market dynamics in the first half of 2026 to be similar to the second half of 2025, noting continued uncertainty in the U.S. academic and government sector regarding NIH budget disbursements.
Jan 12, 2026, 4:15 PM
TXG Announces Preliminary Q4 and Full-Year 2025 Results and Strategic Initiatives
TXG
Guidance Update
Product Launch
New Projects/Investments
- 10x Genomics announced preliminary Q4 2025 revenue of $166 million and full-year 2025 revenue of $599 million, exceeding the high end of their Q4 guide. The company also generated $40 million in cash, bringing its balance sheet to over $500 million.
- The company highlighted its strong product portfolio, including the Chromium platform for single cell analysis and the increasingly preferred Xenium for spatial analysis, with the Flex assay becoming its most popular by volume due to its advanced capabilities and cost-effectiveness.
- Strategic initiatives include leveraging AI for massive biological datasets, expanding into translational research as a key growth driver, and developing future diagnostics applications in oncology and autoimmune diseases.
- To support these initiatives, 10x Genomics plans to establish its own CLIA lab and has announced partnerships with the Cancer Research Institute, Dana-Farber Cancer Institute, and Brigham and Women's Hospital.
Jan 12, 2026, 4:15 PM
10x Genomics Announces Preliminary Q4 and Full Year 2025 Results and Strategic Expansion into Diagnostics and AI
TXG
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- 10x Genomics reported preliminary Q4 2025 revenue of $166 million, exceeding the high end of its guide, and full year 2025 revenue of $599 million. The company also generated $40 million in cash, increasing its balance sheet to over $500 million.
- The company is strategically expanding into translational research and diagnostics, with plans to generate clinical evidence and establish a CLIA lab. Initial partnerships include Dana-Farber Cancer Institute for oncology and Brigham and Women's Hospital for autoimmune disease applications.
- 10x Genomics is positioning its technologies, such as the Chromium platform and Flex assay, to meet the increasing demand for large-scale data sets driven by AI in biology. This includes a partnership with the Cancer Research Institute to build a Discovery Engine for immunotherapy.
- The company acquired Scale Biosciences to integrate its technologies into the Chromium portfolio, enhancing scale capabilities, with minimal financial impact expected at this stage.
Jan 12, 2026, 4:15 PM
10x Genomics Announces Collaboration with Dana-Farber and Plans for CLIA Lab
TXG
New Projects/Investments
- 10x Genomics (TXG) announced a collaboration with Dana-Farber Cancer Institute to analyze tumor samples and identify biomarkers linked to treatment response for cancer therapies.
- The study will utilize 10x's Chromium Flex single cell assay and Xenium spatial platform to create detailed tumor maps and define a clinical reporting framework.
- Concurrently, 10x Genomics plans to establish a CLIA-certified laboratory to provide regulated infrastructure for assay implementation, validation, and future diagnostic services.
- These efforts represent the start of a multi-year research initiative to integrate single cell and spatial tumor analysis into potential diagnostic workflows to support cancer patient care.
Jan 12, 2026, 2:10 PM
10x Genomics Partners with Cancer Research Institute for AI-Driven Immuno-Oncology Initiative
TXG
New Projects/Investments
- 10x Genomics announced a multi-phase collaboration with the Cancer Research Institute (CRI) to advance immuno-oncology through high-resolution molecular data and AI.
- This initiative aims to create one of the world's most comprehensive translational and preclinical immuno-oncology datasets, encompassing over 20,000 samples.
- The project will utilize 10x's Chromium single cell and Xenium spatial platforms, and later the Chromium Flex single cell assay, to profile more than 500 million cells.
- The collaboration seeks to uncover mechanisms of immune response, refine existing treatments, identify new therapeutic strategies, and lay the groundwork for future vaccine discovery in cancer.
Jan 12, 2026, 2:00 PM
10x Genomics Announces Preliminary Q4 and Full Year 2025 Results
TXG
Earnings
Guidance Update
Demand Weakening
- 10x Genomics reported preliminary, unaudited fourth quarter 2025 revenue of approximately $166.0 million, reflecting 1% growth compared to the prior year period, and full year 2025 revenue of approximately $642.8 million.
- Excluding $44.1 million related to patent litigation settlements, full year 2025 revenue was approximately $598.7 million, representing a 2% decrease from the prior year.
- Consumables revenue demonstrated growth, with Q4 2025 consumables revenue at approximately $141.7 million (6% increase year-over-year) and full year 2025 consumables revenue at approximately $507.2 million (3% growth over the prior year).
- The company concluded 2025 with approximately $520 million in cash, cash equivalents, and marketable securities.
Jan 11, 2026, 5:00 PM
10x Genomics Discusses Strategic Positioning, Market Dynamics, and AI Opportunities at Wolfe Research Conference
TXG
Guidance Update
Product Launch
New Projects/Investments
- 10x Genomics (TXG) has undergone significant internal restructuring, including executive team changes and commercial reorganization, positioning the company to "play offense" as the macro environment potentially stabilizes.
- The company is actively managing pricing for single-cell consumables, particularly with the introduction of new product configurations like the Flex assay, to drive volume through market elasticity, aiming for a normalized pricing trend soon.
- TXG believes it is in a strong competitive position due to product performance, quality, and recent launches, effectively closing the price advantage previously leveraged by competitors.
- There is a growing interest in large-scale single-cell programs fueled by AI modeling, which TXG sees as a significant opportunity, with its technology being a key enabler for building these biological models.
- Due to the highly uncertain environment, 10x Genomics is not providing full-year guidance for 2026.
Nov 18, 2025, 4:20 PM
10x Genomics CEO Discusses Market Environment and Strategic Positioning
TXG
Management Change
Product Launch
Demand Weakening
- 10x Genomics underwent a major restructuring and executive team changes approximately a year ago, which has positioned the company to effectively navigate a challenging macro environment.
- The company's commercial restructuring, completed earlier this year, established specialized teams for CapEx instruments, biopharma, and academia, enhancing execution and adaptability despite ongoing market uncertainties, including funding and biopharma spending.
- 10x Genomics is strategically lowering single-cell consumable prices with new product configurations, such as the latest Flex assay, to drive volume and expand applications, anticipating continued volume growth and nearing a pricing equilibrium.
- The company is well-positioned competitively due to superior product performance, quality, and customer satisfaction, with recent product launches effectively addressing price as a competitive factor.
- There is a resurgence of interest in large-scale single-cell projects, driven by AI modeling, with 10x Genomics' technology being a key enabler for potential massive datasets that could transform drug discovery and science.
Nov 18, 2025, 4:20 PM
TXG CEO Discusses Strategic Positioning and Market Dynamics
TXG
Product Launch
New Projects/Investments
Demand Weakening
- 10x Genomics (TXG) CEO Serge Saxonov stated the company is in a strong position to "play offense" following a major restructuring and executive team changes, which have improved its ability to navigate a challenging macro environment.
- The company's strategy of lowering single-cell consumable prices through new product configurations, such as the recently launched Flex assay, is successfully driving volume growth and is expected to lead to a pricing equilibrium soon, enhancing competitive standing.
- There is a resurgence of interest in large-scale single-cell programs, which are being "turbocharged" by AI, creating significant opportunities for investment from biopharma, biotech, and academia to build large biological models.
- TXG maintains a strong competitive position due to product performance, quality, and breadth, and its sequencer-agnostic approach (compatible with Altima and upcoming Roche sequencers) offers superior value to customers.
Nov 18, 2025, 4:20 PM
Quarterly earnings call transcripts for 10x Genomics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more